Cognition Therapeutics, Inc. (CGTX)
CGTXNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.7000
+0.0439 (+6.69%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $64.65m
- P/E
- –
- EPS, last 4 quarters
- $-0.1500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.5501 to $1.81
- Average volume
- –
- Previous close
- $0.6561
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $3.00, +328.6% from here
Earnings
next estimate $-0.0700Next report
Dec 2025
+66.7%
Mar 2026
+16.7%
Jun 2026
+33.3%
Sep 2026
+42.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$13.67m | -$8.82m | -$7.74m | -$7.38m |
| Net income | -$3.34m | -$4.57m | -$3.93m | -$4.14m |
News
8 latest- What Makes Cognition Therapeutics (CGTX) a New Buy StockZacks · 5 days ago
- Cognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To Begin RTTNews · Nov 7, 2026
- Cognition Tx (CGTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- Cognition Therapeutics Q3 Earnings Call HighlightsMarketBeat · Nov 5, 2026
- Cognition Therapeutics, Inc. Receives Nasdaq Deficiency Letter and Reports Third Quarter 2026 Financial ResultsFintel · Nov 5, 2026
- Cognition Therapeutics, Inc. Aligns with FDA on Pivotal Phase 3 Trial of Zervimesine in Dementia with Lewy BodiesFintel · Oct 22, 2026
- Cognition Aligns With FDA On Pivotal Phase 3 Study For Dementia With Lewy Bodies; Stock Up RTTNews · Oct 22, 2026
- Cognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug Zervimesine RTTNews · Sep 29, 2026
The company
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer's disease, geographic atrophy, Parkinson's, among others. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cogrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.